Caladrius Biosciences

400 articles with Caladrius Biosciences

• Caladrius Biosciences Announces Participation in Upcoming Conferences in June 2021

  6/1/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events: NCVH Annual Conference (June 1-4, 2021)

• Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in May 2021

  5/4/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events:

• Caladrius Biosciences to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time

  4/29/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended March 31, 2021 on Thursday, May 6, 2021 at 4:30 p.m. (ET).

• Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease

  3/8/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to the Company’s CD34+ cell therapy product, CLBS12, for the treatment of Buerger’s disease

• Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

  3/3/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021.

• Caladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time

  2/18/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three and twelve months ended December 31, 2020 on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time

• Caladrius Biosciences, Inc. Closes $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules

  2/17/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has closed on its previously announced sale to institutional investors of an aggregate of 24,906,134 shares of its common stock and warrants to purchase up to an aggregate of 12,453,067 shares of common stock

• Caladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules

  2/12/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has entered into securities purchase agreements with several institutional investors to purchase an aggregate of 24,906,134 shares of its common stock

• Caladrius Biosciences Closes $25.0 Million Private Placement

  1/25/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has closed on its previously announced sale of an aggregate of 12,500,000 shares of its common stock and warrants to purchase up to an aggregate of 6,250,000 shares of common stock to several institutional and accredited

• Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in February 2021

  1/25/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in the following virtual conferences in February.

• 

  Clinical Catch-Up: January 18-22

  1/25/2021

  With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.

• Caladrius Biosciences Announces $25.0 Million Private Placement

  1/21/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise $25.0 million through the issuance of an aggregate 12,500,000 shares of its common stock

• Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction

  1/19/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announced that it has treated the first patient in its Phase 2b FREEDOM trial of CLBS16 as a therapy for coronary microvascular dysfunction (“CMD”) at The Christ Hospital Health Network in Cincinnati, Ohio

• Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021

  1/6/2021

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Company’s President and CEO, will participate in the following virtual investor conferences during January 2021. H.C. Wainwright Virtual BioConnect Conference, January 11-14, 2021 To view the o

• Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio UpdateProgram strategy and prioritization supports projection of available capital through 2021

  12/14/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company has completed its year-end strategic portfolio product review to optimize the development strategy and priority of each of its programs for 2021 and beyond. “The Company evaluated its current and proposed devel

• Caladrius Biosciences to Webcast Live at Life Sciences Investor ForumCompany invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com

  12/10/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Company’s President and CEO, will present a live webcast at the Life Sciences Investor Forum on December 17th.

• Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical OfficerThe Company retains Robert Honigberg, M.D., as interim Chief Medical Officer

  11/17/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that Dr. Douglas Losordo, Chief Medical Officer (“CMO”) of the Company, has tendered his resignation in order to explore opportunities outside of Caladrius.

• Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020

  11/10/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces its presentation at American Heart Association’s (“AHA”) Scientific Sessions, being held virtually November 13-17, 2020.

• Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November

  11/4/2020

  - Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in three upcoming virtual investor conferences during November 2020. November 11-16, 2020 LSX Virtual Inv€$tival Showcase November 17-19, 2020 Jefferies Virtual London Healthcare Conferenc e Novemb

• Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors

  11/2/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced the appointment of Anne Whitaker to its Board of Directors. Ms. Whitaker is a seasoned healthcare executive bringing to Caladrius 28 years of experience in the life science industry, including senior leadership roles